Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Molecular Signature of response and potential pathways related to resistance to the HSP90 inhibitor, 17-AAG, in breast cancer.

ABSTRACT: We have done transcriptional profiling of 17-AAG treated (24h, 48H) breast cancer cell lines to understand the mechanisms of the drug action and indicate novel set of pharmacodynamic biomarkers of the drug response as well as of resistance

ORGANISM(S): Homo sapiens

PROVIDER: GSE23209 | GEO | 2010/10/12

SECONDARY ACCESSION(S): PRJNA131637

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Molecular Signature of response and potential pathways related to resistance to the HSP90 inhibitor, 17-AAG, in breast cancer.

Project description:We have done transcriptional profiling of 17-AAG treated (24h, 48H) breast cancer cell lines to understand the mechanisms of the drug action and indicate novel set of pharmacodynamic biomarkers of the drug response as well as of resistance Two-condition experiment, Untreated vs. Treated sensitive cells. Phenotype replicates: 8 untreated replicates, 14 treated replicates.

2010-10-11 | E-GEOD-23209 | biostudies-arrayexpress

Multiplexed proteome dynamics profiling of HSP90 inhibitor 17-AAG

Project description:Investigation of proteostatic effects of HSP90 inhibition by 17-AAG and differentiation of maturation state dependent HSP90 requirements of proteins.

2018-04-05 | PXD008633 | Pride

Drug combination of 17-AAG and Belinostat on MDA-MB-231 breast cancer cells

Project description:Breast cancer is the most common cancer that threatens women's health. While the strategy of drug combination can help to reduce adverse effects and to overcome the resistance of clinical treatment of single drug. In this work, we report the synergetic effect between a HSP90 inhibitor 17-AAG and a HDAC inhibitor Belinostat, on the triple-negative breast cancer MDA-MB-231 cells. The RNA-Seq data analysis showed that the most over-represented KEGG pathways in the combination group came from migration or invasion related genes, which were not observed in the differentially expressed genes after the treatment of 17-AAG or Belinostat alone.

2019-05-17 | GSE129944 | GEO

Expression data from 17-AAG resistance cell line

Project description:Develop the 17-AAG resistance human lung cancer cell line and used microarrays to observe the gene alternnation

2017-01-11 | GSE93384 | GEO

Multiplexed proteome dynamics profiling of HSP90 inhibitor 17-AAG in T-cells

Project description:Investigation of proteostatic effects of HSP90 inhibition by 17-AAG and differentiation of maturation state dependent HSP90 requirements of proteins in resting T-cells.

2018-05-02 | PXD008635 | Pride

Expression data from human colonic cancer cell line SW480 and its acquired 17-AAG resistance cell line SW480-R

Project description:Heat shock protein 90 (HSP90) is a molecular chaperone required for the stability and function of many proteins. The chaperoning of oncoproteins by HSP90 enhances survival, growth and invasive potential of cancer cells. HSP90 inhibitors are promising new anticancer agents, in which the benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin (17-AAG) is currently in clinical evaluation. However, the implications of acquired resistance to this class of drug remain largely unexplored. In the present study, we have generated isogenic human colonic cancer cell line SW480 that is resistant to 17-AAG by continued culturing in the compound. We used microarrays to detail the global programme of gene expression underlying the acquired resistance to 17-AAG in SW480 and SW480-R cell lines.

2015-03-14 | GSE66867 | GEO

Expression profiling of HSP90 inhibitor 17-AAG in anti-CD3 and anti-CD28 stimulated T-cells

Project description:Investigation of expression effects of HSP90 inhibition by 17-AAG of proteins in resting and activated T-cells.

2018-05-02 | PXD008627 | Pride

Multiplexed proteome dynamics profiling of HSP90 inhibitor 17-AAG in anti-CD3 and anti-CD28 stimulated T-cells

Project description:Investigation of proteostatic effects of HSP90 inhibition by 17-AAG and differentiation of maturation state dependent HSP90 requirements of proteins in activated T-cells.

2018-05-02 | PXD008634 | Pride

Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer.

Project description:Gallbladder cancer (GBC) is a lethal cancer with poor prognosis associated with high invasiveness and poor response to chemotherapy and radiotherapy. New therapeutic approaches are urgently needed in order to improve survival and response rates of GBC patients. We screened 130 small molecule inhibitors on a panel of seven GBC cell lines and identified the HSP90 inhibitor 17-AAG as one of the most potent inhibitory drugs across the different lines. We tested the antitumor efficacy of 17-AAG and geldanamycin (GA) in vitro and in a subcutaneous preclinical tumor model NOD-SCID mice. We also evaluated the expression of HSP90 by immunohistochemistry in human GBC tumors.In vitro assays showed that 17-AAG and GA significantly reduced the expression of HSP90 target proteins, including EGFR, AKT, phospho-AKT, Cyclin B1, phospho-ERK and Cyclin D1. These molecular changes were consistent with reduced cell viability and cell migration and promotion of G2/M cell cycle arrest and apoptosis observed in our in vitro studies.In vivo, 17-AAG showed efficacy in reducing subcutaneous tumors size, exhibiting a 69.6% reduction in tumor size in the treatment group compared to control mice (p < 0.05).The HSP90 immunohistochemical staining was seen in 182/209 cases of GBC (87%) and it was strongly expressed in 70 cases (33%), moderately in 58 cases (28%), and weakly in 54 cases (26%).Our pre-clinical observations strongly suggest that the inhibition of HSP90 function by HSP90 inhibitors is a promising therapeutic strategy for gallbladder cancer that may benefit from new HSP90 inhibitors currently in development.

| S-EPMC5432248 | biostudies-literature

Transcription profiling by array of human breast cancer MCF-7 cells treated with 17-AAG

Project description:17-AAG treatment of MCF-7 Microarray <br><br> Files containing additional statistical analysis and data for meta-probesets are available on the FTP site for the experiment, in E-MTAB-339.additional.zip

2011-08-18 | E-MTAB-339 | biostudies-arrayexpress